Neuropsychologic Assessments of Dupilumab-Treated Adolescent Participants With Moderate-to-Severe Atopic Dermatitis
Completed · NCT05203380
Conditions: Moderate-to-severe Atopic Dermatitis
At a glance
- Research payments reported, 2025
- $7,141
- U.S. investigators named
- 0
- Sites paid
- 0
- Planned or actual enrollment
- 45
About the trial
- Sponsor
- Regeneron Pharmaceuticals (with Sanofi)
- Tested
- dupilumab (drug)
- Dates
- Started 2022-01-27; completion 2023-03-10
- Results posted
- Not yet
Primary Objective: Part A * To quantify deficits in cognitive functioning in adolescents with moderate-to-severe AD, using the Conners' Continuous Performance Test 3rd Edition (CPT-3) d' T-score * To determine the entry criterion (CPT-3 d' score) for Part B Primary Objective: Part B * To measure changes in cognitive functioning in adolescents with moderate-to-severe AD treated with dupilumab Secondary Objectives * To evaluate the relationship of cognitive and sensory functioning with severity of AD in adolescent AD patients * To evaluate the relationship between changes in AD severity and changes in cognitive and sensory functioning scores following treatment with dupilumab (Part B only).
From ClinicalTrials.gov, last updated 2023-09-08. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Regeneron Pharmaceuticals, Inc. reported $7,141 in research payments for this study in 2025 (6 payments).
Products named: Dupixent
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
Sites paid to run it
- $7,141
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.